OncoResponse

Please note: The information displayed on this page might be outdated.
OncoResponse: Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology, Immunotherapy, Oncology
Industry
Biotechnology
Investment Participation
CrossOvers, Series C
Listing
Private
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
1124 Columbia Street
Suite 300
Seattle, WA 98104
United States

Company Participants at Fall Private Company Showcase 2021

  • Clifford J. Stocks, CEO/Co-Founder

Upcoming Company Event Participation